Edition:
United States

Pfizer Says Xtandi (Enzalutamide) Plus Androgen Deprivation Therapy (Adt) Met Primary Endpoint


Monday, 11 Feb 2019 05:00pm EST 

Feb 11 (Reuters) - Astellas Pharma Inc <4503.T>::PHASE 3 ARCHES TRIAL SHOWS XTANDI® (ENZALUTAMIDE) SIGNIFICANTLY IMPROVED RADIOGRAPHIC PROGRESSION-FREE SURVIVAL IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.PFIZER INC - XTANDI (ENZALUTAMIDE) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) MET PRIMARY ENDPOINT.PFIZER INC - SECONDARY ENDPOINTS REPORTED SHOWED THAT XTANDI PLUS ADT REDUCED RISK OF PSA PROGRESSION.PFIZER INC - SECONDARY ENDPOINTS REPORTED SHOWED THAT XTANDI PLUS ADT REDUCED RISK OF STARTING A NEW ANTINEOPLASTIC THERAPY COMPARED TO ADT ALONE.